ComplianceOnline

Microbiology Devices; Reclassification of Herpes Simplex Virus Types 1 and 2 Serological Assays

  • Date: December 01, 2009
  • Source: www.fda.gov
Webinar All Access Pass Subscription Abstract:

The Food and Drug Administration (FDA) is implementing a direct final rule correcting the regulation classifying herpes simplex virus (HSV) serological assays by removing the reference to HSV serological assays other than type 1 and type 2. When reclassifying this device, FDA mistakenly distinguished between HSV serological assays type 1 and type 2 and all other HSV serological assays. At that time, and today, the only preamendments HSV serological assays which FDA was aware of were type 1 and type 2 and, therefore, the classification of HSV assays other than type 1 and type 2 was incorrect. FDA is correcting the classification of this device to eliminate possible confusion resulting from this error. Elsewhere in this issue of the Federal Register, we are publishing a companion proposed rule under FDA’s usual procedure for notice and comment to provide a procedural framework to finalize the rule in the event we receive significant adverse comment and withdraw this directfinal rule

Effective Date:This rule is effective December 7, 2009

Bookmark and Share
Best Sellers
You Recently Viewed
    Loading